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Abstract
Background: The complement system is a crucial mediator of inflammation and cell lysis after cerebral ischemia.
However, there is little information about the exact contribution of the membrane attack complex (MAC) and its
inhibitor-protein CD59.
Methods: Transient focal cerebral ischemia was induced by middle cerebral artery occlusion (MCAO) in young
male and female CD59a knockout and wild-type mice. Two models of MCAO were applied: 60 min MCAO and 48
h reperfusion, as well as 30 min MCAO and 72 h reperfusion. CD59a knockout animals were compared to wild-type
animals in terms of infarct size, edema, neurological deficit, and cell death.
Results and Discussion: CD59a-deficiency in male mice caused significantly increased infarct volumes and brain
swelling when compared to wild-type mice at 72 h after 30 min-occlusion time, whereas no significant difference
was observed after 1 h-MCAO. Moreover, CD59a-deficient mice had impaired neurological function when
compared to wild-type mice after 30 min MCAO.
Conclusion: We conclude that CD59a protects against ischemic brain damage, but depending on the gender and
the stroke model used.
Background
Focal cerebral ischemia leads to a primary brain damage
which results from a complex pattern of pathophysiologi-
cal events including excitotoxicity, periinfarct depolariza-
tions, and inflammation [1-4]. The complement cascade
is an important part of the innate immune system and is
a potent mediator of inflammation and cell lysis which is
activated following cerebral ischemia [5-7], and strong
complement activation after ischemic stroke is associated
with unfavourable outcomes [8]. Complement is depos-
ited on apoptotic neurons which likely leads to injury in
adjacent viable cells. Different studies show that blocking
the complement system during the early phase of infarct
evolution protects the penumbra and reduces brain
injury [9,7,10]. The complement regulatory molecule
CD59 represents the major controller of membrane
attack complex (MAC) formation, and is an essential
protector of homologous cells after complement
activation [11]. CD59 is a small protein containing 10
cystein residues which form five disulfide bonds [12]. It
regulates the complement activation cascade at the final
step inhibiting formation of the MAC [13]. CD59 is
anchored to the cell membrane via glycosyl phosphatidyl
inositol (GPI), and expressed ubiquitously on cells which
are in contact with body fluids containing components of
the complement system including cells in the CNS.
Numerous studies indicate that the MAC not only
induces cell lysis but also transduces cell activation when
assembled in sublytic concentrations on cell membranes
[14]. For instance, the MAC has been shown to trigger
the up-regulation of P-selectin and the secretion of von
Willebrand factor in endothelial cells [15]. Moreover, for-
mation of MAC was shown to trigger endothelial
damage, cytotoxicity, and neurodegneration in vivo
[16,17] and deficient expression of CD59 in a rare human
disease (Paroxysmal nocturnal haemoglobinuria) is asso-
ciated with an increased risk of thrombotic events
[18,19]. In a model of renal Ischemia/Reperfusion (I/R), it
was shown that CD59a plays a protective role in injured * Correspondence: george.trendelenburg@charite.de
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also play a protective role in cerebral ischemia.
CD59a is constitutively expressed in neurons, most
probably to protect from so-called autologous “innocent
bystander” cell lysis after complement system activation
in brain injury [21,22]. Nevertheless, because of low
levels of neuronal CD59a expression, the neuronal capa-
city of controlling activation of complement is limited.
This renders neurons susceptible to MAC-driven lysis in
conditions of intracerebral complement activation [11].
Previous in vitro experiments, as well as immunostain-
ing of human brains suggested that oligodendrocytes
can also express low levels of CD59a [21]. CD59a-
knockout mice [18] had a significantly impaired neuro-
logical outcome after experimental closed head injury
and showed a significant exacerbation of cerebral
damage when compared to wild-type controls [11].
Taken together, there is data supporting a protective
effect of CD59a in cerebral ischemia which led us to the
present study, in which we analysed the role of CD59a
in two different standard experimental stroke models by
the use of CD59a knockout mice.
Methods
Animals
Generation and characterization of CD59a knockout mice
was described by Holt et al. (2001) [18]. CD59a-/- mice
were generated on a mixed 129/Sv × C57Bl/6 genetic
background and have been backcrossed to the original
C57Bl/6 background for more than 10 generations. Age-
matched 10 - 12 week old C57Bl/6 mice (BfR, Berlin, Ger-
many) were used as control mice. The animal handling
and surgery were performed in accordance with the
Guidelines for the Use of Animals in Neuroscience Research
(Society for Neuroscience). All experiments were approved
by the local institutional Animal Care Committee,
LAGeSo (No.G0382/05). The mice were bred in a selective
pathogen-free (SPF) environment and under standardized
conditions of temperature (21°C), humidity (60%), light
and dark cycles (12:12 h), with food and water provided
ad libitum.
Induction of focal cerebral ischemia
Middle cerebral artery occlusion (MCAO) was induced
by inserting a silicone-coated 8/0 nylon monofilament
(Xantopren M Mucosa and Activator NF Optosil Xan-
topren, Heraeus Kulzer, Wehrheim, Germany) via the
internal carotid artery as described by Hara et al. (1996)
[23]. Sufficiency of occlusion and reperfusion of the
middle cerebral artery (MCA) was monitored by Laser
Doppler flowmetry (Peri Flux 4001 Master, Perimed,
Stockholm, Sweden). Mice were anaesthetized with 2%
isoflurane for induction and maintained with 1.5% iso-
flurane in 70% N2O and 30% O2 via a face mask.
Anesthesia did not exceed 10 minutes. We used two dif-
ferent MCAO- models, one with a short ischemic inter-
val (30 min) and 72 h of reperfusion [24], as well as one
with a more prolonged occlusion (60 min and 48 h of
reperfusion). Thirty minutes of MCAO leads to selective
neuronal injury and pronounced inflammation in the
striatum with little involvement of neocortical struc-
tures, while 60 min MCAO produces extensive striatal
and neocortical infarction. After 30 minutes (‘mild
model’), or 1 h (’severe model’) of ischemia the animals
were re-anaesthetized and the filament was removed to
permit reperfusion. During surgery and ischemia, body
temperature was controlled by a temperature feedback
controlled heating plate and maintained between 37.0
and 37.5°C. There was no significant difference of the
mean body weight between the different groups. All
experiments were performed in a randomized manner
by investigators blinded to the groups as described and
recommended recently by Dirnagl et al. (2009) [25].
Neurological score
The neurologic dysfunction was determined using a neu-
rological score (NSC) described by Bederson [26] and
modified by Hara [23]. Neurological deficits were graded
in wild-type and CD59a knockout mice after MCAO on
a scale of: 0 - no deficit/1- failure to extend right fore-
paw/2 - circling to the contralateral side/3 - loss of pos-
tural reflex/4 - death. The NSC was assessed at the
time-points 24 h, 48 h and 72 h after induction of cere-
bral ischemia for 30 min (mild model), or 1 hour (severe
model). Task performance was evaluated in a blinded
fashion with regard to the animal groups. Differences
between wild-type and CD59a-knockout mice were ana-
lysed statistically by the Mann-Whitney U test.
Assessment of infarct volume
Two (60 min MCAO), or three (30 min MCAO) days
after induction of ischemia, mice were deeply anaesthe-
tized and sacrificed. The brains were removed rapidly
from the skull and snap frozen in 2-methylbutane on dry
ice. Brains were sectioned (12 μm) on a cryostat in differ-
ent coronal cryosections (positions see below), dried
overnight, and stained with hematoxylin (Merck, Darm-
stadt, Germany). The sections were digitized, the area of
infarction was quantified by using Sigma Scan Pro; Ver-
sion 5.0.0 Software (Jandel Scientific, San Rafael, CA,
USA), and infarct volumes were calculated. Brain swel-
ling was calculated by subtracting the size of the whole
contralateral (non-infarcted) hemisphere from the whole
ispilateral (infarcted) hemisphere. Animals without an
infarct or with only a small infarct in the hippocampus
were excluded from these measurements because insuffi-
cient induction of cerebral ischemia was assumed. Infarct
sizes of male, female, or mixed gender CD59a-deficient
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mals with matching gender. Statistical analysis was per-
formed by using the Mann-Whitney-U-Test.
Genotyping
Every knockout mouse used in this study was genotyped
before use, which was performed using the REDExtract-
N-Amp Tissue PCR kit (Sigma-Aldrich) with DNA
extracted from mice tails and the following primers:
Intron 3 (5’-GGT GAC CAA CTG GTG TTA ACA AAG
GG-3’), neomycin ‘-( 5 ’-GAA CCT GCG TGC AAT CCA
TCT TG-3’), and exon 3-(5’G C TA C CA C TG T TT C C
AAC CGG TG-3’). Amplification of the wild-type gene
resulted in an amplicon of 212 bp, DNA derived from
CD59a-ko mice produced an amplicon of 450 bp.
Immunohistochemistry
Immunohistochemistry was performed on fresh frozen
tissue harvested at different times of reperfusion. From
fresh frozen tissue 12 μm coronal cryosections at inter-
aural positions 6.6, 5.3, 3.9, 1.9, and 0 mm were thaw-
mounted onto glass slides. Adjacent sections were used
to determine stroke volume (see above). Slides were air-
dried and fixed in -20°C methanol and acetone (1:1). The
sections were incubated in blocking solution containing 3
% normal goat serum and 0.3 % Triton X-100 (Sigma).
The slides were incubated 2 h at room temperature with
a polyclonal rat anti-CD11b antibody (Chemicon) which
stains macrophages/monocytes and microglia. For the
detection of primary antibody, slides were incubated with
Cy3-conjugated goat anti-rat IgG (Invitrogen) at 1:400
for 1 h at room temperature. Slides were also counter-
stained with Hoechst 33258, which stains DNA (Invitro-
gen GmbH; Karlsruhe, Germany). The whole ipsilateral
hemispheres of three sections each animal (n = 3) were
counted using stereo investigator 7 (MicroBrightField
Bioscience, Williston, USA).
Terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL)
The Fluorescein in Situ Cell Death Detection Kit (Roche
Diagnostics GmbH, Mannheim, Germany) was used for
TUNEL stain. Adjacent slides for immunohistochemical
staining (see above) were used for the detection of
damaged cells. Slides were dried and fixed in 4% forma-
lin solution. After washing, the sections were incubated
in ice-cold ethanol-acetic acid solution (3:1) for 10 min
followed by incubation for 1 h in 3% Triton-X 100
(Sigma-Aldrich). Next, sections were incubated with
TdT-enzyme in reaction buffer containing fluorescein-
dUTP for 90 min at 37°C. Enzyme was omitted for the
negative control. After washing, slides were also coun-
terstained with Hoechst 33258 (Invitrogen GmbH;
Karlsruhe, Germany). All sections were evaluated after
staining using Leica stereo investigator 7 (MicroBright-
Field Bioscience, Williston, USA).
Statistical analysis
For comparison of infarct volumes and neurological def-
icit Mann-Whitney-U-test was used, if not stated other-
wise. P-values below 0.05 were considered statistically
significant. Power calculation was performed using
SISA-Binominal [27]. Based on the known variance of
previous experiments the MCAO experiments were
powered (a = 0.05; b = 0.8) to detect effect sizes d [28]
of at least 1, i.e. of one standard deviation.
Results
CD59a-deficiency increases infarct volume in mild
experimental stroke, but not in the more severe
stroke model
First, we analysed whether CD59a-deficiency alters the
size of the infarcted area in two different models of cer-
ebral ischemia: a more severe stroke model (60 min
occlusion time) and a mild one (30 min occlusion time).
When infarct volumes of male and female CD59a-
deficient mice and matching wild-type mice were
compared after 1 h MCAO and 48 h of reperfusion, no
significant difference between CD59a-knockout mice and
wild-type mice, either in males (values are given as median
[25
th percentile, 75
th percentile]: CD59am-/-: 108 mm
3
[96 mm
3, 164 mm
3]; WTm: 129 mm
3 [123 mm
3, 144
mm
3], in females (CD59af-/-: 129 mm
3 [98 mm
3,1 4 5
mm
3]W T f: 130 mm
3 [109 mm
3,1 4 3m m
3], or in the
mixed-gender group was detected (CD59amix-/-: 119 mm
3
[94 mm
3, 147 mm
3]W T mix: 130 mm
3 [113 mm
3,
144 mm
3]) (Figure 1A,C,E). There was also no significant
difference of brain swelling after 60 min MCAO and 48 h
reperfusion between CD59a-knockout and wild-type mice
of either gender (median: CD59amix-/-: 46 mm
3;W T mix:
56 mm
3) (Figure 1B,D,F). For Type II error considerations,
see Methods (Statistics).
However, when mice were subjected to the second
stroke model (30 min MCAO), a statistically significant
increase of the infarct volume was observed in
male CD59a-knockout mice and in CD59a-knockout
mice of mixed gender when compared to wild-type mice
at 72 h of reperfusion (difference of the infarct volume
in the mixed gender group, given as median [25
th percen-
tile, 75
th percentile]: CD59amix-/-: 74 mm
3 [57 mm
3,
113 mm
3]; WTmix:5 7m m
3 [23 mm
3,8 7m m
3];
p = 0.029) (Figure 2A). The difference was statistically
s i g n i f i c a n to n l yi nm a l em i c e( i n f a r c tv o l u m ei nm a l e
mice: CD59am-/- 77 mm
3 [57 mm
3, 112 mm
3]v s .W T m:
46 mm
3 [20 mm
3,7 4m m
3] p = 0.020; infarct volumes in
female mice: CD59af-/- 60 mm
3 [42 mm
3, 109 mm
3]v s .
WTf:7 8m m
3 [34 mm
3,9 5m m
3]) (Figure 2C,E). Brain
swelling correlated with infarct volumes, because brain
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Page 3 of 12Figure 1 Comparison of infarct volume and brain swelling of CD59a-deficient and wild-type-mice (C57BL/6) after 60 min MCAO. Infarct
volumes (A, C, E), and brain swelling (B, D, F), given as box-and-whisker plots, at 48 h of reperfusion after induction of ischemia are visualized
for both, CD59a-deficient (CD59a-/-) and wild-type (WT) mice, of both genders (A, B)( n=2 2 CD59a-/- mix;n=1 6 WT mix) as well as male (C, D)
(nCD59a-/- m = 11; nWT m = 6) and female (E, F)( n CD59a-/- f = 11; nWT f = 10) mice separately. Statistical analysis was performed using the Mann-
Whitney-U-test. The indirect infarct volume was calculated as the volume of the difference between contralateral hemisphere and the non-
infarcted volume of the ipsilateral hemisphere. There is no significant difference between infarct sizes of CD59-ko mice and wild-type mice. In all
box plots, the top of the box represents the 75th percentile, the bottom of the box represents the 25th percentile, and the line in the middle
represents the 50th percentile (median). The whiskers (the lines that extend out the top and bottom of the box) represent the highest and
lowest values that are not outliers or extreme values.
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Page 4 of 12Figure 2 Comparison of infarct volume and brain swelling of CD59a-deficient and wild-type-mice (C57BL/6) after 30 min MCAO. Infarct
volumes (A, C, E), as well as volume of brain swelling (B, D, F) given as box-and-whisker-plots are visualized. Statistical analysis was performed
with the Mann-Whitney-U-test (*: p ≤ 0.05). In contrast to 1 h MCAO-model (figure 1), after 30 min MCAO and 72 h of reperfusion there was a
significant difference of infarct volumes and brain swelling between wild-type and CD59a-deficient mice in both, mixed gender and male mice:
infarct volumes were larger and brain swelling increased in male CD59a knockout mice (nCD59a-/- m = 22; nWT m = 18), as well as in knockout
mice of mixed gender (n = 25CD59a-/- mix;n=2 4 WT mix), when compared to age- and gender-matched wild-type control mice. No significant
differences were seen for female mice. In all box plots, the top of the box represents the 75th percentile, the bottom of the box represents the
25th percentile, and the line in the middle represents the 50th percentile. The whiskers (the lines that extend out the top and bottom of the
box) represent the highest and lowest values that are not outliers or extreme values.
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ischemic and nonischemic hemisphere - was significantly
increased in CD59a-/- male mice (median: CD59am-/-:
33 mm
3;W T m:1 4m m
3) and mixed gender (median:
CD59amix-/-: 31 mm
3;W T mix:1 6m m
3), but not female
mice (Figure 2B,D,F).
CD59a-deficiency leads to increased apoptosis only in the
more severe experimental stroke
Next, we compared the amount of TUNEL-positive cells
in CD59a-deficient and wild-type mice in both models,
because we speculated that MAC-inhibition by CD59a
may influence the amount of apoptotic cell death, which
depends on the stroke model used [24,29]. TUNEL-posi-
tive cells were mostly found in the infarct border zone
(’penumbra’), the extend and location of which depends
on the stroke model used: e.g. compare amount of
TUNEL-positive cells in the different sections of both
models (Figure 3A,B). Indeed, there was a significant
increase of TUNEL-positive cells found in the ischemic
hemisphere of male CD59a-deficient mice at 48 h after
60 min MCAO when compared to wild-type controls
(Figure 3 and 4). Since infarct volumes did not differ
significantly, this observation argues against a pure ‘sec-
ondary effect’, meaning that the amount of apoptotic
cells only depends on the size of the infarct volume. On
the other hand, the amount of TUNEL-positive cells did
not differ significantly between CD59a-deficient and
wild-type mice when the mild stroke model (30 min
MCAO/72 h reperfusion) was used (Figure 3).
CD59 deficiency has no influence on CD11b-positive cell
accumulation in post-ischemic brain tissue
Because sublytic MAC deposition was recently shown to
be associated with the release of proinflammatory cyto-
kines (e.g. TNFa) and chemotactic factors (IL-8) [15,30],
the post-ischemic inflammatory response was determined
in CD59a-deficient mice and wild-type mice by counting
CD11b-positive cells in the ischemic hemisphere. Stain-
ing with CD11b, which stains invading macrophages/
monocytes as well as activated microglia, revealed that
there was no significant alteration of CD11b-positive
cells in the ischemic hemisphere of CD59a-ko mice (sec-
t i o n1 :3 0 1±4[ 6 0m i nM C A O ] ,2 5 2±6 1[ 3 0m i n
MCAO]; section 2: 410 ± 123 [60 min MCAO], 365 ± 96
[30 min MCAO]); section 3: 600 ± 342 [60 min MCAO],
1 8 8±5 2[ 3 0m i nM C A O ] )w h e nc o m p a r e dt ot h a to f
wild-type mice (section 1: 337 ± 110 [60 min MCAO],
162 ± 102 [30 min MCAO]; section 2: 530 ± 197 [60 min
MCAO], 437 ± 34 [30 min MCAO]; section 3: 575 ± 286
[60 min MCAO], 259 ± 102 [30 min MCAO]) in both
models (48 h after 60 min MCAO; 72 h after 30 min
MCAO) (data not shown).
CD59a-deficient mice have a worse neurological deficit
when compared to wild-type mice after 30 min MCAO
To investigate if CD59a-deficiency also influences the
neurological outcome after cerebral ischemia, CD59a-
knockout as well as wild-type control mice of mixed
gender were subjected to experimental stroke with two
different occlusion times (MCAO for 30 min, respectively
60 min). The neurological deficit was determined at differ-
ent times of reperfusion after induction of cerebral
ischemia.
Neither at 24 h nor at 48 h reperfusion time was there a
significant difference of the neurological deficit between
CD59a-ko (n = 24) and wild-type mice (n = 21) when mid-
dle cerebral artery was occluded for 60 min (Figure 5).
However, in contrast to the findings with the
more severe stroke model, a significant neurological dete-
rioration (p < 0.05) was observed after 30 min occlusion
of the middle cerebral artery (mild stroke model) in
Figure 3 TUNEL-positive cell count in post-ischemic mouse brain tissue after 30 min and 60 min MCAO. Absolute counts of TUNEL
(apoptotic and necrotic)-positive cells in whole ischemic brain hemispheres of male wild-type and CD59a-deficient mice, determined in different
brain sections. A: TUNEL-positive cell counts in MCAO-model 1 (60 min MCAO), B: cell counts in MCAO-model 2 (30 min MCAO). Distance to
bregma: a, 5.3 mm; b, 3.9 mm; and c, 1.9 mm (*: p < 0.05, SD, unpaired t-test, n = 3 per group).
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when compared to the wild-type mice. At all three time
points examined (24 h, 48 h, and 72 h after induction of
MCAO), there was a significant increase in the neurologi-
cal deficit (p24 h = 0.047; p48 h = 0.014; p72 h = 0.025 as cal-
culated by Mann-Whitney U test) in CD59a-deficient mice
(n = 27) when compared to wild-type control mice
( n=2 7 ) .M a l em i c es h o w e do n l yas i g n i f i c a n td i f f e r e n c e
after 48 h and 72 h (p48 h = 0.0042; p72 h = 0.007)
(Figure 6).
Discussion
This study demonstrates that deficiency of the comple-
ment regulator protein CD59a exacerbates post-ischemic
brain damage in vivo in a gender-specific way and
depending on the severity of the stroke.
The complement system has been recently identified
as a conductor of inflammation triggering further tissue
damage in experimental ischemia [31]. Activation of the
complement system mediates secondary brain injury,
which leads to increased infarct volumes, a pronounced
inflammatory response, and a worse neurological deficit
[32,33]. Recent studies indicated that both, the classical
and the mannose-binding lectin (MBL) complement
pathways trigger complement activation [6,34,35], but
the alternative pathway also appears to play a crucial
role in neuronal death [36,37]. Complement activation
results in the release of chemotactic factors (e.g. C3a,
C5a) and finally in the formation of the terminal pore-
forming complex, the membrane attack complex
(MAC), by complement components C5b-9. Formation
of sublytic concentrations of the MAC was shown to
induce the release of several pro-inflammatory cytokines
(e.g., TNF-a) and chemotactic factors including IL-8
and monocyte chemoattractant protein (MCP)-1 [15,38].
However, the exact contribution of the MAC to the
Figure 4 Representative images of TUNEL-positive cells in post-ischemic mouse brain tissue after 60 min MCAO and 48 h reperfusion.
TUNEL (apoptotic and necrotic)-positive cells (B, D) in ischemic brain tissue of the infarct border zone (penumbra) of male wild-type (C, D) and
CD59a-deficient mice (A, B). A,C: staining of cell nuclei using Hoechst 33258, which stains DNA (Invitrogen, Germany).
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remained unclear. The complement regulator protein
CD59 is known to inhibit MAC formation by preventing
the incorporation and polymerization of C9 on cell
membranes [13]. CD59a has been characterized as the
primary regulator of MAC assembly in the mouse, since
the expression of the second CD59 isoform in mice,
CD59b, was found to be restricted to testis [39].
Thus, we used CD59a-deficient mice to study the role
of MAC and its inhibitory protein CD59a in focal
cerebral ischemia. Our data reveal that the presence of
CD59a improves neurological outcome, decreases brain
swelling, and reduces infarct volume after 30 min of
transient focal cerebral ischemia in the mouse. We have
previously shown an increased neurological deficit in
CD59a-knockout mice when compared to wild-type
mice in a model of traumatic brain injury [11]. More-
over, a stroke study in neonatal rats, naturally lacking
C9 - which is part of the terminal MAC - demonstrated
an increase of infarct volumes in neonatal rats when
Figure 5 Comparison of neurological dysfunction of CD59a-deficient and wild-type-mice (C57BL/6) after 60 min MCAO. Either 24 h after
reperfusion (A, C, E) or 48 h after reperfusion (B, D, F) there is no significant difference in neurological dysfunction, neither in male (C, D) nor in
female (E, F) mice group when comparing CD59-deficient mice to wild-type (WT) mice. Statistical analysis was performed using the Mann-
Whitney-U-test. Score of 0: no neurological dysfunctions; score 1: failure to extend right forepaw, score 2: circling to the contralateral side; score
3: loss of postural reflex and score 4: death. Number of animals: for CD59a-ko n = 24, WT n = 21. Both male and female animals were used in
this study.
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to efficiently protect human NT2-N neuronal cells
against complement-mediated cell injury [41,42].
Our data revealed that significant protection by the pre-
sence of CD59a is gender-specific and is only achieved in
male mice. This differencem i g h tb ee x p l a i n e db yt h e
influence of hormonal fluctuations in female mice. Gen-
der-specific neuroprotective effects have been also found
by others [43-45]. A substantial amount of data indicates
that progesterone, a gonadal hormone and neurosteroid
naturally distributed in the human brain, has potent neu-
roprotective properties [46,47]. In animal studies, proges-
terone reduced cerebral edema, neuronal loss and
behavioral deficits by inhibiting secondary injury cascade
[48-52]. Safety and efficacy phase I and II trials have been
succesfully conducted in recent clinical trials [53,54]. It
appears that the gender-specific neuroprotective effects
seen in the present study may be related to progesterone-
mediated beneficial effects in female animals.
Moreover, the degree of protection by CD59a depends
on the stroke model used and was only observed in the
stroke model with the more selected neuronal death
(mild stroke model). This observation fits well with the
data of Yamada et al. [55], which observed only a syner-
gistic effect of CD59a deficiency (together with CD55) in
renal ischemia. The prolonged occlusion interval (60 min
MCAO) leads to a significant increase of TUNEL-positive
cells in the CD59a-deficient mice when compared to
wild-type mice, which is in good agreement with the
findings of Turnberg et al. [20], who obtained similar
results using CD59a-/- mice in a model of renal ischemia.
It was recently shown that ischemia leads to a rapid
loss of membranous CD59 protein in the ischemic core
region [41,6]. Thus, we alternatively speculate that the
longer occlusion interval in the 60 min MCAO model
may dampen local CD59a-expression, so that the
remaining CD59a expression in the wild-type mice
(CD59a+/+) is of minor relevance when compared to
Figure 6 Comparison of neurological dysfunction of CD59a-deficient and wild-type-mice (C57BL/6) after 30 min MCAO. The CD59-ko
mice in the mixed gender group show 24 h after reperfusion (A), 48 h after reperfusion (B) and 72 h after reperfusion (C) a significant increased
neurological dysfunction (p < 0,05) compared to wild-type (WT) mice. In the male gender group (D, E, F) there is only a significant difference
after 48 h (E) and 72 h (F). No increase was observable in the female group (G, H, I). Statistical analysis was performed using the Mann-Whitney-
U-test. A score of 0 shows no neurological dysfunctions; score 1: failure to extend right forepaw, score 2: circling to the contralateral side; score
3: loss of postural reflex and score 4: death. Number of animals: for CD59a-ko n = 27, WT n = 27. Both male and female animals were used in
this study.
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mice. An alternative explanation may be that both mod-
els (30 min vs. 60 min occlusion interval) are character-
ized by different degrees of complement activation: in
the postischemic brain tissue of the 30 min MCAO
model complement activation may only result in sublytic
MAC-concentrations, so that the MAC-mediated effects
not directly result in cell lysis (as it may be the case in
the 60 min MCAO model), but rather contribute to the
secondary brain injury by the induction of proinflamma-
tory chemokines, which renders the postischemic
damage more dependent on MAC-inhibition. We postu-
late that CD59a-deficiency mainly contributes to postis-
chemic neuronal damage by increasing MAC-induced
neuronal cell death, but that this effect is further
increased by the modulation of the innate immune sys-
tem (invading leukoycytes as well as activated glia) as
reviewed by Griffiths et al. (2009) [56]. Nevertheless, the
different reperfusion intervals in both models used do
not allow a direct comparison of infarct outcomes.
Accordingly, effects of CD59a-deficiency differ signifi-
cantly in renal ischemia, depending on the time point
used for evaluation [20,55].
MAC formation was recently shown to trigger up-reg-
ulation of pro-inflammatory cytokines, chemotactic fac-
tors, as well as adhesion molecules such as P-Selectin,
E-selectin and ICAM-1 in activated endothelial cells
[15,30,38]. Nevertheless, we did not detect a significant
increase of the inflammatory cell accumulation in the
CD59a-deficient mice when compared to wild-type
mice. This observation may be due to the more promi-
nent effect of other chemoattractant proteins, which
were upstream of the MAC in the complement cascade
(e.g. C3a, C5a), and which were not affected by CD59a
expression. An alternative explanation may be that the
part of the inflammatory response which is based on the
MAC-driven induction of pro-inflammatory genes is not
detected at the time points studied in our setting and
may be more relevant at earlier time points as observed
by [57].
Nevertheless, our study is in good agreement with var-
ious reports, that show an improved neurological func-
tion after experimental stroke in animals treated with
complement-inhibitors [33], treated with the comple-
ment-depleting agent cobra venom factor [58,9], or in
animals which lack complement components, e.g. C3-
deficient mice [59]. The ongoing debate of whether the
complement system is ‘friend or foe’ in ischemic brain
i n j u r y[ 6 0 ]m a yb ee x p l a i n e db yt h ec o m p l e x i t yo ft h e
system and the manifold pathways which are activated
by the complement system, and the different ways com-
plement may be inhibited at different levels of the com-
plement cascade. Thus, our data which demonstrates
model- and gender-specific effects of MAC-inhibition by
CD59a, replenishes the current understanding of the
complement system in ischemic brain injury and thus
may contribute to the development of future therapeuti-
cal strategies [61].
Conclusions
Based on the data, we conclude that the complement
inhibitor protein CD59 is protective after cerebral ische-
mia in a gender specific way, and that this effect
depends on the severity of the cerebral damage. In a
mild model of cerebral ischemia with selective neuronal
cell death, CD59 leads to less neuronal dysfunction and
a smaller infarct volume. However, the exact mechan-
isms of complement MAC-induced neuronal cell death
after cerebral ischemia require further investigation.
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